# Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

Source: https://onco.cc/trials/nct07235176/  
OnCo record `nct07235176` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.

## Summary

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients is a phase 1/2 interventional study registered as NCT07235176 by Qilu Pharmaceutical Co., Ltd., with 300 participants planned, started 2026-01-16 and due to reach its primary completion in 2028-11-02. Interventions recorded: QLS1304 tablet+Fulvestrant or QLC1401 and QLS1304 tablet+Fulvestrant，AI or QLC1401+CDK4/6i.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07235176
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Study to Evaluate Safety, Preliminary Efficacy and PK Characteristic of QLS1304 Combined With Endocrine Therapy in ER+/HER2- Breast Cancer Patients
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT07235176: https://clinicaltrials.gov/study/NCT07235176

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07235176.json